Deciphering the code: the pivotal role of lncRNAs in advancing TNBC therapy DOI Creative Commons
Weiping Chen, Zhiyong Pan,

Zhengfu Feng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 2, 2024

Triple-negative breast cancer (TNBC) represents the most formidable subtype of cancer, characterized by a notable dearth in targeted therapeutic options. Deciphering underlying molecular mechanisms TNBC is pivotal for improving patient outcomes. Recent scientific advancements have spotlighted long non-coding RNAs (lncRNAs) as key players genesis, progression, and metastasis cancers. This review delineates significant influence lncRNAs on advancement, detection, neoadjuvant chemotherapy efficacy TNBC, detailing diverse expression patterns aberrant lncRNAs. The paper explores specific which regulate gene both nucleus cytoplasm, with special focus their involvement TNBC’s post-transcriptional landscape. Thorough investigations into TNBC-associated not only forge new avenues early diagnosis potent treatment strategies but also highlight these molecules promising targets, heralding an era personalized precision medicine management.

Language: Английский

Chitosan: An Overview of Its Properties, Solubility, Functional Technologies, Food and Health Applications. DOI
Great Iruoghene Edo, Winifred Ndudi,

Ali B. M. Ali

et al.

Carbohydrate Research, Journal Year: 2025, Volume and Issue: 550, P. 109409 - 109409

Published: Jan. 31, 2025

Language: Английский

Citations

4
Revolutionizing Prostate Cancer Therapy: Artificial intelligence – based Nanocarriers for Precision Diagnosis and Treatment DOI
Moein Shirzad,

Afsaneh Salahvarzi,

Sobia Razzaq

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104653 - 104653

Published: Feb. 1, 2025

Language: Английский

Citations

4
Bacterial Systems as a Precision Delivery Platform of Therapeutic Peptides for Cancer Therapy DOI Creative Commons
Jinyuan Liu, Guizhi Shen, Xuehai Yan

et al.

Polymer science & technology., Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Language: Английский

Citations

1
Magnetic Nanoparticles and Drug Delivery Systems for Anti-Cancer Applications: A Review DOI Creative Commons

W Donald Graham,

M. V. Torbett,

A. B. Islam

et al.

Nanomaterials, Journal Year: 2025, Volume and Issue: 15(4), P. 285 - 285

Published: Feb. 13, 2025

Cancer continues to be a prominent fatal health issue worldwide, driving the urgent need for more effective treatment strategies. The pressing demand has sparked significant interest in development of advanced drug delivery systems chemotherapeutics. advent nanotechnology offers groundbreaking approach, presenting promising pathway revolutionize cancer and improve patient outcomes. Nanomedicine-based have demonstrated capability improving pharmacokinetic properties accumulation chemotherapeutic agents sites while minimizing adverse side effects. Despite these advantages, most NDDSs exhibit only limited improvement during clinical trials. recent magnetic nanoparticles (MNPs) biomedical applications revealed potential opportunity further enhance performance NDDSs. MNPs can utilized increase targeting capabilities NDDSs, controlled release agents, weaken chemoresistance tumors with hyperthermia. In this review, we will explore advancements research oncology applications, how their augment when complexed them emphasize challenges safety concerns incorporating into treatment.

Language: Английский

Citations

1
Targeting and combating drug resistance in triple-negative breast cancer using nano polymer: Efficacy of A6 peptide-PLGA-PEG nanoparticle loaded with doxorubicin and anti-miR-21 inin vitroandvivo model DOI

Zaidah Ibrahim,

Pei Pei Chong,

Hasan Al-Moustafa

et al.

Published: Jan. 4, 2025

Abstract Triple-negative breast cancer (TNBC) poses a significant challenge in treatment due to the emergence of drug resistance standard chemotherapeutics, along with associated risks non-targeted tissues. This study is dedicated developing nanoparticle delivery system utilizing PLGA-PEG nanoparticles (NP) integration A6 peptide (NPA6) as specific targeting ligand for TNBC. Encapsulating Doxorubicin (DOX) and antisense-miR-21 (AM21), these are designed counter vitro vivo. Characterized by an average size 103.5 (±8.1) nm remarkable DOX encapsulation efficiency, have been successfully engineered. Results demonstrate that NPA6.DOX.AM21 effectively mitigates resistance, displaying significantly decreased doxorubicin IC 50 opposed free (2.5 µM vs 25.7µMrespectively, p<0.01). In mice models, peptide-incorporated formulation (NPA6.DOX, NPA6.DOX.AM21) exhibits substantial tumour reduction increased concentration within tumours, all while minimizing non-specific exposure compared non-A6 formulations (NPDOX, FREE DOX) treatments. innovative PLGA-PEG-A6 complex loaded AM21 showcases superior efficacy surmounting cell line, progression, decreasing distribution organs mice. These results hold promise enhanced combat against precise chemotherapy, hence potentially improving patient outcomes survival rates. Graphical abstact Figure abstract study. Fron left right, development followed characterization vivo reduce target triple negative (TNBC). PLGA: polylactic-co-glycolic acid, PEG: polyethylene glycol, A6: peptide, DOX: Doxorubicin, AM21: antisense-microRNA -21 Highlights The conjugated co-loaded anti-miRNA21 (NPA6.DOX.AM21) was fabricated 99.8 - diameter PDI 0.2 high drugs efficiency. death, reduced MDA MB-231 resistant cells, dose. targeted TNBC size, tumor less accumulation off-target organs, comparison control model.

Language: Английский

Citations

0
Reactivating T cell immunity in Wnt-hyperactivated non-small cell lung cancer through a supramolecular droplet of carnosic acid and peptide DOI Creative Commons
Na Liu, Y.D. Tu, Hanyu Wang

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101309 - 101309

Published: April 1, 2025

Language: Английский

Citations

0
Peptide-based drugs in immunotherapy: current advances and future prospects DOI

Dipanjan Karati,

Shreyasi Meur,

Soumi Das

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: April 23, 2025

Language: Английский

Citations

0
Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress DOI Creative Commons
Krishna Jadhav, Ashwin Abhang, Eknath Kole

et al.

Bioengineering, Journal Year: 2025, Volume and Issue: 12(5), P. 481 - 481

Published: April 30, 2025

Peptide–drug conjugates (PDCs) have emerged as a next-generation therapeutic platform, combining the target specificity of peptides with pharmacological potency small-molecule drugs. As an evolution beyond antibody–drug (ADCs), PDCs offer distinct advantages, including enhanced cellular permeability, improved drug selectivity, and versatile design flexibility. This review provides comprehensive analysis fundamental components PDCs, homing peptide selection, linker engineering, payload optimization, alongside strategies to address their inherent challenges, such stability, bioactivity, clinical translation barriers. Therapeutic applications span oncology, infectious diseases, metabolic disorders, emerging areas like COVID-19, several advancing in trials achieving regulatory milestones. Innovations, bicyclic peptides, supramolecular architectures, novel technologies, are explored promising avenues enhance PDC design. Additionally, this examines trajectory emphasizing potential highlighting ongoing that exemplify efficacy. By addressing limitations leveraging advancements, hold immense promise targeted therapeutics capable complex disease states driving progress precision medicine.

Language: Английский

Citations

0
Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin – an approach for enhanced cancer therapy DOI Creative Commons
Dawid Szymczuk, Karolina H. Markiewicz, Katarzyna Niemirowicz-Laskowska

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(18), P. 14246 - 14258

Published: Jan. 1, 2025

This study explores the effectiveness against selected cancer cell lines of nano-engineered formulations composed inorganic cores with steroid-based polymeric shells functionalized either a targeting or chemotherapeutic agent.

Language: Английский

Citations

0
Deciphering the code: the pivotal role of lncRNAs in advancing TNBC therapy DOI Creative Commons
Weiping Chen, Zhiyong Pan,

Zhengfu Feng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 2, 2024

Triple-negative breast cancer (TNBC) represents the most formidable subtype of cancer, characterized by a notable dearth in targeted therapeutic options. Deciphering underlying molecular mechanisms TNBC is pivotal for improving patient outcomes. Recent scientific advancements have spotlighted long non-coding RNAs (lncRNAs) as key players genesis, progression, and metastasis cancers. This review delineates significant influence lncRNAs on advancement, detection, neoadjuvant chemotherapy efficacy TNBC, detailing diverse expression patterns aberrant lncRNAs. The paper explores specific which regulate gene both nucleus cytoplasm, with special focus their involvement TNBC’s post-transcriptional landscape. Thorough investigations into TNBC-associated not only forge new avenues early diagnosis potent treatment strategies but also highlight these molecules promising targets, heralding an era personalized precision medicine management.

Language: Английский

Citations

2